Audentes Therapeutics (BOLD) Earns Media Impact Rating of 0.04

Media stories about Audentes Therapeutics (NASDAQ:BOLD) have trended somewhat positive on Saturday, according to Accern Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Audentes Therapeutics earned a news impact score of 0.04 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 46.1194819249047 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

These are some of the media stories that may have impacted Accern Sentiment’s scoring:

Audentes Therapeutics (BOLD) traded up $0.18 during mid-day trading on Friday, hitting $27.57. 183,915 shares of the company traded hands, compared to its average volume of 233,472. Audentes Therapeutics has a one year low of $13.90 and a one year high of $33.43.

Audentes Therapeutics (NASDAQ:BOLD) last posted its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.88) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.88). analysts anticipate that Audentes Therapeutics will post -3.53 EPS for the current year.

Several brokerages have recently weighed in on BOLD. ValuEngine cut Audentes Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Leerink Swann reiterated an “outperform” rating and set a $29.00 price target (up from $22.00) on shares of Audentes Therapeutics in a research report on Wednesday. Zacks Investment Research cut Audentes Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, August 8th. Evercore ISI began coverage on Audentes Therapeutics in a research report on Wednesday, August 16th. They set an “outperform” rating and a $23.00 price target on the stock. Finally, William Blair began coverage on Audentes Therapeutics in a research report on Tuesday, October 17th. They set an “outperform” rating and a $35.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. Audentes Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $27.17.

ILLEGAL ACTIVITY WARNING: This article was posted by Community Financial News and is owned by of Community Financial News. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at https://www.com-unik.info/2017/11/18/audentes-therapeutics-bold-earns-media-impact-rating-of-0-04.html.

In other Audentes Therapeutics news, VP Suyash Prasad sold 8,000 shares of the company’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $21.44, for a total value of $171,520.00. Following the completion of the sale, the vice president now owns 8,000 shares of the company’s stock, valued at $171,520. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP David Nagler sold 3,750 shares of the company’s stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $25.00, for a total value of $93,750.00. Following the completion of the sale, the senior vice president now directly owns 3,750 shares of the company’s stock, valued at approximately $93,750. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 776,500 shares of company stock worth $21,712,130. 47.30% of the stock is owned by company insiders.

About Audentes Therapeutics

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Insider Buying and Selling by Quarter for Audentes Therapeutics (NASDAQ:BOLD)

What are top analysts saying about Audentes Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Audentes Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit